View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 14, 2022

Avrobio receives orphan drug designation for Hunter syndrome gene therapy

Avrobio is expected to initiate a Phase I/II clinical trial for Hunter syndrome in partnership with the University of Manchester.

Avrobio has received orphan drug designation for its gene therapy, AVR-RD-05, from the US Food and Drug Administration (FDA) to treat mucopolysaccharidosis type II (MPSII) or Hunter syndrome.

The rare and seriously debilitating lysosomal disorder, Hunter syndrome primarily affects young boys and is caused by a deficiency in the lysosomal enzyme iduronate-2-sulfatase (IDS).

AVR-RD-05 makes use of the own hematopoietic stem cells (HSCs) of a patient that are transduced ex vivo with a lentiviral vector encoding the human IDS enzyme.

The company noted that this gene therapy is the fourth one to receive orphan drug designation.

AVR-RD-05 had previously obtained rare pediatric disease designation from the FDA.

Next year, Avrobio is expected to initiate a collaborator-sponsored Phase I/II clinical trial for Hunter syndrome in partnership with the University of Manchester, UK.

University of Manchester cell and gene therapy professor Brian Bigger developed the programme.

Affecting an estimated one in 100,000 to one in 170,000 male individuals across the globe, Hunter syndrome causes devastating complications in the body.

These complications include severe neurological, cardiac and respiratory dysfunction, hearing impairment and skeletal malformations.

The FDA grants orphan drug designation to drugs and biologics that are intended to treat, diagnose or prevent rare diseases or conditions safely.

Furthermore, this status provides some incentives that may include tax credits for clinical trial costs and prescription drug user fee waivers.

In May, Avrobio reported preliminary data from a collaborator-sponsored Phase I/II clinical trial evaluating the safety of its investigational gene therapy AVR-RD-04 for cystinosis, a progressive disease which is marked by the buildup of cystine in cellular organelles.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology